334 related articles for article (PubMed ID: 27339764)
1. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
Kristiansen RG; Rose CF; Ytrebø LM
Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
[TBL] [Abstract][Full Text] [Related]
2. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
Kristiansen RG
Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
[TBL] [Abstract][Full Text] [Related]
3. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Jalan R; Wright G; Davies NA; Hodges SJ
Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
[TBL] [Abstract][Full Text] [Related]
4. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
[TBL] [Abstract][Full Text] [Related]
5. Ornithine phenylacetate revisited.
Jover-Cobos M; Noiret L; Sharifi Y; Jalan R
Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516
[TBL] [Abstract][Full Text] [Related]
6. Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia.
Dadsetan S; Sørensen M; Bak LK; Vilstrup H; Ott P; Schousboe A; Jalan R; Keiding S; Waagepetersen HS
Biochem Pharmacol; 2013 Jan; 85(1):115-23. PubMed ID: 23103564
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
8. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.
Jover-Cobos M; Noiret L; Lee K; Sharma V; Habtesion A; Romero-Gomez M; Davies N; Jalan R
J Hepatol; 2014 Mar; 60(3):545-53. PubMed ID: 24512823
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for hyperammonemia.
Hadjihambi A; Khetan V; Jalan R
Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
[TBL] [Abstract][Full Text] [Related]
10. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
[TBL] [Abstract][Full Text] [Related]
11. Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
Hadjihambi A; De Chiara F; Hosford PS; Habtetion A; Karagiannis A; Davies N; Gourine AV; Jalan R
Hepatology; 2017 Apr; 65(4):1306-1318. PubMed ID: 28066916
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR
Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476
[TBL] [Abstract][Full Text] [Related]
13. Clinical science workshop: targeting the gut-liver-brain axis.
Patel VC; White H; Støy S; Bajaj JS; Shawcross DL
Metab Brain Dis; 2016 Dec; 31(6):1327-1337. PubMed ID: 26446022
[TBL] [Abstract][Full Text] [Related]
14. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
Jamshidzadeh A; Heidari R; Abasvali M; Zarei M; Ommati MM; Abdoli N; Khodaei F; Yeganeh Y; Jafari F; Zarei A; Latifpour Z; Mardani E; Azarpira N; Asadi B; Najibi A
Biomed Pharmacother; 2017 Feb; 86():514-520. PubMed ID: 28024286
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the treatment of hyperammonemia.
Matoori S; Leroux JC
Adv Drug Deliv Rev; 2015 Aug; 90():55-68. PubMed ID: 25895618
[TBL] [Abstract][Full Text] [Related]
16. Ammonia-lowering strategies for the treatment of hepatic encephalopathy.
Rose CF
Clin Pharmacol Ther; 2012 Sep; 92(3):321-31. PubMed ID: 22871998
[TBL] [Abstract][Full Text] [Related]
17. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
[TBL] [Abstract][Full Text] [Related]
18. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
19. Gut ammonia production and its modulation.
Romero-Gómez M; Jover M; Galán JJ; Ruiz A
Metab Brain Dis; 2009 Mar; 24(1):147-57. PubMed ID: 19067141
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.
Holecek M
Metab Brain Dis; 2014 Mar; 29(1):9-17. PubMed ID: 23996300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
